Come up with a name for your new list and we'll add to it:
Oligomerix raised a round of funding on September 11, 2013. Investors include
National Institutes of Health.
Oligomerix is a biopharmaceutical company focused on development of small molecule inhibitors, immunotherapeutic approaches and biomarkers targeting tau oligomers and their newly discovered proteolyti…